Cardiff by the Sea, CA, United States of America

Gary S Hahn

This inventor holds 35 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 3 EPO patents, primarily in Topical Pain Relief. Top assignees: Immunetech Pharmaceuticals, Galleon Labs LLC, Cosmederm Technologies. Active years: 1986-2026.

USPTO Granted Patents = 35 (Patent Applications = 9)

% Patents Active = 88.6

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 1.3

ph-index = 16

Forward Citations = 869(Granted Patents)

Location History:

Solana Beach, CA (US) (1986)
Cardiff, CA (US) (1989)
Adell, WI (US) (2005)
Cardiff by the Sea, CA (US) (1991 - 2013)
San Diego, CA (US) (1986 - 2023)

Company Filing History:

8 out of 9

Immunetech Pharmaceuticals

Cosmederm Technologies

patents

4. 4 out of 4

Cosmederm Bioscience, Inc.

patents

5. 2 out of 23

Dura Pharmaceuticals, Inc.

9. 6 out of 834,307

Other

patents

Years Active: 1986-2026

Loading Chart...

Areas of Expertise:

Topical Formulations

Strontium Compounds

Pain Relief

Inflammation Treatment

Skin Irritation

Immunotherapeutic Agents

Peptide Antagonists

Non-IgE-Mediated Diseases

Alginate Compounds

Fragrance-Emitting Containers

Mist Generators

Sensory Nerve Inhibition

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12636311 - Topically administered strontium-containing complexes for treating pain, pruritis and inflammation (2026-05-26),

2. 12121536 - Strontium based compositions and formulations for pain, pruritus, and inflammation (2024-10-22),

3. 11801261 - Topically administered strontium-containing complexes for treating pain, pruritis and inflammation (2023-10-31),

4. 11337989 - Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound (2022-05-24),

5. 11235002 - Strontium based compositions and formulations for pain, pruritus, and inflammation (2022-02-01),

6. 10874689 - Topically administered strontium-containing complexes for treating pain, pruritis and inflammation (2020-12-29),

7. 10159693 - Strontium-containing complexes for treatment of pain, pruritis and inflammation (2018-12-25),

8. 9480704 - Topically administered strontium-containing complexes for treating pain, pruritis and inflammation (2016-11-01),

9. 9333185 - Topically administered strontium-containing complexes for treating pain, pruritis and inflammation (2016-05-10),

10. 8449923 - Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin (2013-05-28),

11. 8147855 - Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium (2012-04-03),

12. 7404967 - Topical product formulations containing strontium for reducing skin irritation (2008-07-29),

13. 6928682 - Ice tool (2005-08-16),

14. 6455076 - Formulations and methods for reducing skin irritation (2002-09-24),

15. 6139850 - Formulations and methods for reducing skin irritation (2000-10-31),

Title: Gary S. Hahn: Innovator in Therapeutically-Active Compositions

Introduction: Gary S. Hahn, based in Cardiff by the Sea, California, has made significant contributions to the field of therapeutically-active compositions. With an impressive portfolio of 34 patents, he stands out as an inventor dedicated to advancing treatments for pain, inflammation, and related conditions.

Latest Patents: Gary's latest patents focus on strontium-based compositions and formulations designed to address pain, pruritus, and inflammation. His innovative work includes therapeutically-active compositions that not only treat pain and irritation but also manage wounds, particularly those at high risk for infection. His formulations involve strontium and beta hydroxybutyrate, which can be applied topically to enhance their effectiveness. Additionally, he has developed strontium-containing complexes that combat both acute and chronic irritation, thereby improving patient outcomes in managing neuropathic conditions.

Career Highlights: Over his career, Gary has worked with prominent companies such as Immunetech Pharmaceuticals. His professional journey reflects a commitment to exploring and expanding the therapeutic potential of novel compositions, making a lasting impact on pain management strategies.

Collaborations: Throughout his career, Gary has collaborated with notable co-inventors, including David O. Thueson and David R. Williams. These partnerships have enriched his work, allowing for a diverse range of insights and innovations in the realm of therapeutically-active compounds.

Conclusion: Gary S. Hahn exemplifies the spirit of innovation in the pharmaceutical field. His extensive patent portfolio underscores his dedication to improving the quality of life for individuals suffering from pain and inflammation-related conditions. As he continues to develop new formulations, Gary's contributions will undoubtedly pave the way for future advancements in therapeutic treatments.